Lyell Immunopharma Stock Today
| LYEL Stock | USD 1.51 0.05 3.21% |
Performance0 of 100
| Odds Of DistressOver 60
|
Lyell Immunopharma is selling for 1.51 as of the 23rd of September 2024. This is a 3.21 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.47. Lyell Immunopharma has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Lyell Immunopharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of October 2022 and ending today, the 23rd of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of June 2021 | Category Healthcare | Classification Health Care |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Lyell Immunopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 256 M outstanding shares of which 13.76 M shares are now shorted by private and institutional investors with about 21.51 trading days to cover. More on Lyell Immunopharma
Moving together with Lyell Stock
Moving against Lyell Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Lyell Stock Highlights
| CEO President | Lynn MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLyell Immunopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lyell Immunopharma's financial leverage. It provides some insight into what part of Lyell Immunopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lyell Immunopharma (LYEL) is traded on NASDAQ Exchange in USA. It is located in 201 Haskins Way, South San Francisco, CA, United States, 94080 and employs 224 people. Lyell Immunopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 386.56 M. Lyell Immunopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 256 M outstanding shares of which 13.76 M shares are now shorted by private and institutional investors with about 21.51 trading days to cover.
Lyell Immunopharma currently holds about 655.56 M in cash with (163.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.64, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lyell Immunopharma Probability Of Bankruptcy
Ownership AllocationLyell Immunopharma maintains a total of 256 Million outstanding shares. Over half of Lyell Immunopharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Lyell Ownership Details
Lyell Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sc China Holding Ltd | 2024-06-30 | 3 M | |
| Fmr Inc | 2024-06-30 | 2.7 M | |
| Mic Capital Management Uk Llp | 2024-06-30 | 1.7 M | |
| Opaleye Management Inc | 2024-06-30 | 1.7 M | |
| Northern Trust Corp | 2024-06-30 | 1.4 M | |
| Charles Schwab Investment Management Inc | 2024-06-30 | 1.3 M | |
| Td Asset Management Inc | 2024-06-30 | 1 M | |
| Balyasny Asset Management Llc | 2024-06-30 | 985.3 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 843.3 K | |
| Mwg Management Ltd. | 2024-06-30 | 20.2 M | |
| Orland Properties Ltd | 2024-06-30 | 15.1 M |
Lyell Immunopharma Historical Income Statement
Lyell Stock Against Markets
Lyell Immunopharma Corporate Management
| Elizabeth Homans | CEO Director | Profile | |
| Richard Goold | Chief Officer | Profile | |
| Stephen Hill | Chief Officer | Profile | |
| Crystal MD | Founder Advisor | Profile | |
| Charles Newton | Chief Officer | Profile | |
| Prof MD | Founder Advisor | Profile | |
| Nellie Dillery | Director Accounting | Profile |
Additional Information and Resources on Investing in Lyell Stock
When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Quarterly Revenue Growth (0.52) | Return On Assets (0.19) | Return On Equity (0.32) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.